How to choose and prepare patients for CAR T-cell therapy?

During the European Society of Hematology (ESH) 2nd How I manage: CAR T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma Hub spoke to Catherine Thieblemont, Hôpital Saint-Louis, Paris, FR. We asked, How to choose and prepare patients for chimeric antigen receptor (CAR) T-cell therapy?

Firstly, Thieblemont discusses the importance of assessing a patient’s disease characteristics and the dynamic nature of the tumor when selecting patients for CAR T-cell therapy. Then, she mentions T-cell fitness as a factor impacting CAR T-cell use in treatment and highlights this as a key discussion point at congress.